




RealRate

PHARMACEUTICAL 2019

Ocuphire Pharma Inc.
Rank 286 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Ocuphire Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ocuphire Pharma Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 239% points. The greatest weakness of Ocuphire Pharma Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 204% points.

The company's Economic Capital Ratio, given in the ranking table, is -434%, being 103% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	15,900
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	0
Liabilities, Non-Current	0
Other Assets	31
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	5,480
Other Net Income	6,169
Property and Equipment	112
Research and Development	13,109
Revenues	0
Selling, General and Administrative Expense	7,429

Output Variable	Value in 1000 USD
Assets	16,043
Liabilities	5,480
Expenses	20,538
Stockholders Equity	10,563
Net Income	-14,369
Comprehensive Net Income	-14,369
Economic Capital Ratio	-434%